Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.35 |
| ▸ | PDE2A | O00408 | 5/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.34 |
| ▸ | FPR1 | P21462 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29601355 | 1.00 | POLB (0.36) | POLBGAANPC1RAB9AHIF1A | |
| SCHEMBL24801175 | 0.90 | KMT2A (0.38) | POLBGAANPC1RAB9AHIF1A | |
| SCHEMBL29600795 | 0.90 | POLB (0.38) | POLBGAANPC1RAB9APDE2A | |
| SCHEMBL24398058 | 0.90 | POLB (0.38) | POLBGAANPC1RAB9APDE2A | |
| SCHEMBL30304260 | 0.89 | POLB (0.36) | POLBGAANPC1RAB9AHIF1A | |
| SCHEMBL24801649 | 0.89 | POLB (0.36) | POLBGAANPC1RAB9AHIF1A | |
| SCHEMBL29601380 | 0.88 | POLB (0.37) | POLBGAANPC1RAB9ASCN9A | |
| SCHEMBL24397817 | 0.88 | POLB (0.37) | POLBGAANPC1RAB9ASCN9A | |
| SCHEMBL24397911 | 0.88 | POLB (0.39) | POLBGAANPC1RAB9AHIF1A | |
| SCHEMBL24393950 | 0.83 | PTPN1 (0.36) | GAAPDE2AMAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399287-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-12-14 | — | — | US | disclosed |
| WO-2022269251-A1 | ACRYLAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | SITRYX THERAPEUTICS LIMITED (GB) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022090724-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399287-A1 | NOVEL COMPOUNDS | CNKSR1, RORC, HLA-DRB1 | POLB 3757/4885GAA 2798/4885NPC1 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.